{"id":"c3459c96-63ba-50b1-90ef-2cccbc439a05","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-tnbc-xenograft","predicate":"decreases_in_recorded_comparison","statement":"Apigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"152804f1-384e-56a1-a11c-ad5159ae0837","mechanism_event_label":"Apigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"b01bbba3-c019-5bd6-8f9f-715624fd9199","slug":"api-tnbc-xenograft-growth","display_name":"Growth of apigenin-treated human-cell xenografts in mice","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"152804f1-384e-56a1-a11c-ad5159ae0837","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-tnbc-xenograft-event","event_type":"experimental_observation","label":"Apigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.","description":"### api-tnbc-xenograft\n\nApigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.\nXenografts contain human tumor cells in mice. Patient-transcriptome comparisons were observational datasets, not treated patients.\nModel and exposure: 25 mg/kg for 28 days; Figure 6, n=12; route not extracted here.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer. | 2023 | https://pubmed.ncbi.nlm.nih.gov/38092740/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10719380/ | https://doi.org/10.1038/s41419-023-06342-6 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin regimen","sequence_order":0,"notes":""},{"entity":{"id":"b01bbba3-c019-5bd6-8f9f-715624fd9199","slug":"api-tnbc-xenograft-growth","display_name":"Growth of apigenin-treated human-cell xenografts in mice","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin regimen\", \"comparator\": \"Vehicle\", \"endpoint\": \"Apigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"25 mg/kg for 28 days; Figure 6, n=12; route not extracted here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer. | https://pubmed.ncbi.nlm.nih.gov/38092740/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10719380/ | https://doi.org/10.1038/s41419-023-06342-6","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-tnbc-xenograft; Xenografts contain human tumor cells in mice. Patient-transcriptome comparisons were observational datasets, not treated patients.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3c31dbec-d322-5bb7-b5e5-9d969cb39b2b","evidence_kind":"source_excerpt","locator":"Lines 700-706","start_line":700,"end_line":706,"excerpt":"### api-tnbc-xenograft\n\nApigenin reduced MDA-MB-231 xenograft growth and shifted selected tumor splice patterns in the reported mouse experiment.\nXenografts contain human tumor cells in mice. Patient-transcriptome comparisons were observational datasets, not treated patients.\nModel and exposure: 25 mg/kg for 28 days; Figure 6, n=12; route not extracted here.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer. | 2023 | https://pubmed.ncbi.nlm.nih.gov/38092740/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10719380/ | https://doi.org/10.1038/s41419-023-06342-6 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"25 mg/kg for 28 days; Figure 6, n=12; route not extracted here.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}